anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Colorectal cancer is a major cause of cancer-related deaths within the Australian population. Colonoscopy and polypectomy represent effective forms of prevention. Factors such as diabetes, hypertension and dyslipidaemia have been linked to adenoma development across a range of ethnicities, however there are limited data from the Australian population. This study investigates established and potential risk factors for early colorectal neoplasia in an Australian population. This was a prospective, observational case-control study in subjects aged 20-85 years, referred for outpatient colonoscopy. Clinical, anthropometric, and biochemical variables were collected at baseline. Polyps were classified as conventional adenomas or sessile serrated lesions, and correlated with clinical and biochemical variables. The study included 357 subjects, median age 55 years (IQR: 43.0-64.0), and 52.9% were female. 41.7% had metabolic syndrome. Multiple positive associations were observed in those over 40 years and with a BMI ≥ 25, including any polyp (aOR: 2.26; 95%CI: 1.22-4.18); adenoma (aOR: 2.64; 95%CI: 1.31-5.31); and, non-advanced adenoma (aOR: 2.66; 95%CI: 1.25-5.68). Our study demonstrates that elevated BMI is an independent risk factor for colorectal neoplasia in Australians undergoing colonoscopy. Further efforts should be focused on both diet and weight optimization in the general population given these findings and the recent national statistics indicating that almost two-thirds of the population are either overweight or obese.
Obstructive sleep apnea syndrome (OSAS) is characterized with recurrent collapse of upper airway during sleep and resulted in hypoxia and sleep fragmentation, which resulted in cardiovascular diseases, metabolic disorders and neurocognitive dysfunctions. The cardiovascular complications attributed to OSAS included hypertension, coronary artery disease, heart failure and stroke. The mechanisms responsible for developments of cardiovascular sequelae included repeated episodes of hypoxia and hypercapnia, exaggerated negative intrathoracic pressure and bursts of sympathetic activity provoking surges in blood pressure and heart rate. Increase of inflammatory mediators, which included C-reactive protein, oxidative stress, adhesion molecules, vascular endothelial growth factor and proinflammatory cytokines, were thought to involve in the developments of cardiovascular diseases in patients with OSAS.

To clarify the exact mechanisms of OSAS and the linkage to cardiovascular complications, in our previous study, we used oligo microarray to genome-wide profile the gene expression patterns in OSAS patients and the changes of gene expressions before and after four-week CPAP treatment. The oligo-microarray data were processed with CRSD database and two-way hierarchical clustering method. The results showed the gene expression patterns were different between control subjects and OSA patients and CPAP treatment also altered the gene expression patterns. Totally 27 genes and four pathways were identified as target genes and pathways from comparing the gene pattern changes before and after CPAP treatment, which included apoptosis, oxidative phosphorylation, cell adhesion and activation and metabolism. To continue analyzing the gene pattern changes before and after CPAP treatment, we propose this three-year project to achieve the following goals: (1) To verify the differentially expressed genes and pathways between normal and OSA patients, and OSA patients before and after CPAP treatment. (2) To correlate the confirmed genes with the clinical presentations and CPAP effects in another 50 OSAS subjects to validate the altered gene expressions and pathways involved. (3) To establish a cell model to investigate the differentially expressed genes and the putative biological pathways involved in OSA syndrome. The information obtained by this approach is very useful to understand the pathogenic mechanism of OSA that leads to systemic complications and further therapeutic intervention may therefore be possible.
The study group includes 38 post neck dissection surgeries with shoulder dysfunction patients treated with fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller) for 30 min., each session includes three games exercise (Dance loop, Tennis and Boxing) with 10 min. for each game and 1 min. rest in between; in addition to their physical therapy program (Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles) 2 sessions per week for 2 months.
Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months. Ventilation machines make it possible to carry out remote monitoring, with the help of healthcare providers.
Polyuria-polydipsia syndrome can be caused by central diabetes insipidus, nephrogenic diabetes insipidus or primary polydipsia. To avoid confusion with diabetes mellitus, the name 'central diabetes insipidus' was changed in 2022 to arginine vasopressin (AVP) deficiency and 'nephrogenic diabetes insipidus' was renamed as AVP resistance. To differentiate the three entities, various osmotic and non-osmotic copeptin-based stimulation tests have been introduced in the past decade. The hypertonic saline test plus plasma copeptin measurement emerged as the test with highest diagnostic accuracy, replacing the water deprivation test as the gold standard in differential diagnosis of the polyuria-polydipsia syndrome. The mainstay of treatment for AVP deficiency is AVP replacement with desmopressin, a synthetic analogue of AVP specific for AVP receptor 2 (AVPR2), which usually leads to rapid improvements in polyuria and polydipsia. The main adverse effect of desmopressin is dilutional hyponatraemia, which can be reduced by regularly performing the so-called desmopressin escape method. Evidence from the past few years suggests an additional oxytocin deficiency in patients with AVP deficiency. This potential deficiency should be further evaluated in future studies, including feasible provocation tests for clinical practice and interventional trials with oxytocin substitution.
Patients receive rituximab IV on day 1 and rituximab and hyaluronidase human SC on days 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 2 cycles 8 weeks apart in the absence of disease progression or unacceptable toxicity. Patients may receive rituximab IV on days 8, 15, and 22 of each cycle if rituximab and hyaluronidase human is not available. Patients who experience PD will be permitted to crossover to arm I at week 12. Patients also receive FDG and undergo PET/CT at baseline and end of treatment. Patients who are positive at pre-treatment bone marrow biopsy also receive FDG and undergo PET/CT on study. Patients also undergo bone marrow biopsy and tissue biopsy at baseline, and blood sample collection throughout the trial. Patients may also undergo bone marrow biopsy and tissue biopsy at end of treatment.
Patients with late fibrovascular sequelae of radiation or of combined radiation and surgery, with quantifiable symptomatology or disability, will be eligible for this trial. This protocol is designed as an open label one arm study. (A placebo controlled randomized trial was approved by the IRB but after extensive negotiation, drug and placebo in slow release formulation will not be provided by the manufacturer). Up to fifty patients will be recruited. After initial assessment of their condition by specified clinical and laboratory parameters, each of the patients will be treated for 8 weeks at the standard pentoxifylline dose (400 mg po TID). Objective and subjective response parameters will be re-assessed at the end of the treatment and 8 weeks later for possible decay of response.

In addition to symptomatic objective and subjective response, blood and urine will be collected for TNF, TGF-beta, and FGF. Cutaneous blood flow and collagen subtyping will be performed on a subset of patients using Laser Doppler, functional MRI techniques and subcutaneous tissue biopsies. We will examine for correlation between clinical response and these biological responses.
The incidence of urinary incontinence (UI) in women increases with age but, unbeknownst to many, it is not a normal part of aging and, in most cases, can be effectively treated. Yet today, the majority of senior women go untreated due to a lack of both human and financial resources. In Canada, there are currently 3 million senior women. Over the next 15 years their numbers are expected to grow significantly, as will the incidence of UI. The number of senior women requiring treatment, let alone the future demand, makes it imperative that more cost-effective treatments be identified. The prevalence of UI in community- dwelling women 65 and over is high - 55% experience stress or urge UI, or even both, and of these, 20 to 25% are classified as having severe symptoms. Not only is UI a serious medical condition but it is also undeniably a social problem, engendering embarrassment and negative self-perceptions. It is associated with reduced social interactions and physical activities, with poor self-rated health, impaired emotional and psychological well-being and impaired sexual relationships. Moreover, it doubles women's risk of being admitted to a nursing home, independent of age or the presence of any other co-morbid conditions. It severely undermines a woman's right to healthy aging. Without doubt, this pervasive and serious condition requires immediate attention. Demographics, the negative impact on older women's functional autonomy and the current unmet treatment needs alone renders improving continence care for older women a priority for the Institute of Aging. This study aims to evaluate if group- based physiotherapy treatment is at least as good as individualized one-on-one physiotherapy treatment for treating urinary incontinence in aging women. The treatment efficacy will be assessed in 364 women (aged 60 years and older) suffering from stress or mixed urinary incontinence and recruited in 4 hospitals and in the community.
The large common bile duct stones (CBDS) remains a therapeutic challenge in ERCPs. Large CBDS are generally refractory to be removed by EST and stone extraction balloons and or baskets. Traditional rescue therapy was the technique of stone fragmentation using ML. The previous reports have shown that EST with ML was successful in the fragmentation of large stones yielding stone clearance rate from 68 t0 79 %. EST-LBD has been shown favorable outcome in the treatment of large bile duct stone. A meta-analysis comparing the effectiveness and complications between EST-LBD and EST in the management of CBDS showed that EST-LBD was as effective as EST for the removal of large or difficult of CBDS in terms of stone clearance in the first ERCP session of 87.87 % vs. 84.15 % and overall clearance of 97.35 % vs. 96.35 % but EST-LBD was associated with fewer complications as well as reduced need for ML compared to EST. The efficacy of EST-ML versus EST-LBD as a therapy for relatively large CBDS, a mean stone size \> 20 mm in currently not well defined. The investigators, herein, compared the efficacy and complications between EST followed by LBD or ML for the removal of CBDS \> 15 mm with a mean stone size \> 20 mm.
PURPOSE: To obtain a cosmetic compsn. remarkably effectively suppressing the loss of water in a horny layer and restoring a damaged water isolating layer. CONSTITUTION: This cosmetic compsn. consists of components (A), (B) and (C). The component A is a molecule having at least two hydrocarbon chains and one polar head group so as to satisfy relation represented by the formula 0.5<(V/ao lc )<=1.0. The component B is a molecule having at least one long hydrocarbon chain and one polar head group. The component C promotes the formation of a double lipid layer and stabilizes the layer formed in this compsn. The molar ratio of A:B:C is 1:(1.5-6.0):(1.1-8.0).
The present application relates to systems and methods for identifying people and/or identifying and quantifying pain, fatigue, mood, and intent while preserving privacy. The disclosed techniques enable, among other things, identification and characterization of a person's mental perception (e.g., pain, fatigue, mood) and/or intent (e.g., intent to perform an action) for medical, safety, home care, and other purposes. Applications requiring long-term patient monitoring are of great interest, such as tracking disease progression (e.g., multiple sclerosis), or monitoring treatment or rehabilitation efficacy. Thus, longitudinal data must be acquired over time to obtain the identity and other characteristics of the person (e.g., pain level, use of a cane). However, the conventional method of person recognition (e.g., photography) acquires unnecessary personal information, thereby causing privacy problems. The disclosed techniques allow measurements to be performed and function with partial or incomplete measurements while preserving privacy, making them robust against real-world (noisy, uncontrolled) environments, such as in a person's home, whether alone or resident with others.
PURPOSE: A composition for treating or preventing colitis including the saponin is provided to control IL-1 beta, IL-6, and expression of tumor necrosis factor alpha, thereby effective for colitis treatment. CONSTITUTION: A composition for treating or preventing colitis comprises lancemacide X, echinocystic acid 3-O-β-Dglucuronopyranoside: EAG, or saponin of echinocystic acid as an active ingredient. The saponin is isolated from Condonopsis lanceolata Trautv fermentation product. The colitis is either ulcerative colitis or Crohn's disease. The pharmaceutical composition for colitis treatment or prevention comprises codonopsis lanceolata which includes Condonopsis lancemacide X, echinocystic acid 3-O-β-Dglucuronopyranoside: EAG, or saponin of echinocystic acid as the active ingredient. The fermentation product is obtained by extracting of codonopsis lanceolata after fermentating or fermentating codonopsis lanceolata extracts. The fermentation is lactobacillus fermentation. A food composition for colitis improvement or prevention comprises Condonopsis lancemacide X, echinocystic acid 3-O-β-Dglucuronopyranoside: EAG, or saponin of echinocystic acid as the active ingredient.
CKD patients stage 5 (eGFR \< 15 ml/min/1,73m²) or stages 4 with abrupt worsening renal function requiring dialysis treatment immediately, followed or not by nephrologists prior to renal replacement therapy (RRT) indication, that agree to initiate peritoneal dialysis (PD) in less than 48 hours after implantation of the peritoneal catheter, without family training or adequacy of the home. The patient must not have any absolute contraindications to initiate PD, which include: presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2\> 70%); abdominal infections; severe hyperkalemia with changes characteristic in ECG; and acute pulmonary edema. These patients will be treated with HD.
Ganciclovir for Injection, USP must be reconstituted and diluted under the supervision of a healthcare provider and administered as intravenous infusion. Each 10 mL clear glass vial contains 543 mg ganciclovir sodium equivalent to 500 mg of ganciclovir. Wearing disposable gloves is recommended during reconstitution and when wiping the outer surface of the vial and the table after reconstitution. The contents of the vial should be prepared for administration in the following manner:

1.Reconstitution Instructions:

a) Reconstitute lyophilized Ganciclovir for Injection, USP by injecting 10 mL of Sterile Water for Injection, USP, into the vial. Do not use bacteriostatic water for injection containing parabens. It is incompatible with Ganciclovir for Injection, USP and may cause precipitation. 

b) Gently swirl the vial in order to ensure complete wetting of the product. Continue swirling until a clear reconstituted solution is obtained.

c) Visually inspect the reconstituted solution for particulate matter and discoloration prior to proceeding with infusion. Discard the vial if particulate matter or discoloration is observed .

d) Reconstituted solution in the vial is stable at room temperature (25°C (77°F)) for 12 hours. Do not refrigerate or freeze. Discard any unused portion of the reconstituted solution.

2.Infusion Instructions:

a) Based on patient weight, the appropriate volume of the reconstituted solution (ganciclovir concentration 50 mg/mL) should be removed from the vial and added to an acceptable infusion fluid (typically 100 mL) for delivery over the course of 1 hour. Infusion concentrations greater than 10 mg/mL are not recommended. The following infusion fluids have been determined to be chemically and physically compatible with Ganciclovir for Injection, USP solution: 0.9% Sodium Chloride, 5% Dextrose, Ringer’s Injection and Lactated Ringer’s Injection, USP.

b) Ganciclovir for Injection, USP, when reconstituted with Sterile Water for Injection (non-bacteriostatic) and further diluted with 0.9% sodium chloride injection or other acceptable infusion fluid as specified above, should be used within 24 hours of dilution to reduce the risk of bacterial contamination. The diluted infusion solution should be refrigerated (2°C to 8°C (36° to 46°F)). Do not freeze.
The education group received extended physical activity education program. The physical activity education was integrated into health promotion-nutrition education program.The education program was applied twice (the baseline and 2-month follow-up).
INTRODUCTION: One of the most adverse chemical factors of the outdoor environment is pesticides entering the organism of newborns via mother's breast milk, and also receive a pesticide load through a polluted environment. The heavy demonstration of pesticides impact on the brain is violation of autonomic regulation mechanisms of newborns' cardiac rhythm. The purpose of the study is early detection of violation of autonomic regulation mechanisms of cardiac function of children with perinatal hypoxia in the region of hexachlorocyclohexane use in cotton planting.
MATERIAL AND METHODS: The hygienic state of the environment of the cotton planting region has been studied by means of measurement of pollution level of the atmospheric air, water and soil with pesticide hexachlorocyclohexane, the concentration of which was in 7,55-9,38 more than their maximum permissible concentration (MPC). 148 children took part in the study who were treated in neonatal center of Turkestan Regional Children's Clinical Hospital in Shymkent city. 30 infants without any signs of hypoxic-ischemic syndrome were assigned to the comparison group (I group). 118 children with signs of hypoxic-ischemic central nervous system injury were included in the study group and were divided into 1 and 2 subgroups. Among them 85 children with detected hypoxic-ischemic central nervous system injury of I-II degree were included in the 1st subgroup, and 33 children with cerebral hypoxic-haemorrhagic central nervous system damage of III degree in the 2nd subgroup. The study has been carried out by means of Holter monitoring using instrumental-software system "Kardiotechnika-4000" within 15-38 days of infants' lives.
RESULTS: Advanced complex of QRS prevails in infants who underwent a heavy perinatal hypoxia. Changes in this electrocardiogram are one of the most unfavorable heart changes and is indicative of bioelectric myocardium instability. Using a program to compare short records of cardiac rhythm, the average daily value of the indicator was calculated. The use of such method enables elimination of such impact of long-term malignant causes in the spectrum. The analysis of heart vegetative reaction conducted among infants of 15-22-day age demonstrated decrease of parasympathetic impact on heart rate of I group infants, and activity of sympathetic segment of vegetative nervous system was unchanged. So, the decrease of parasympathetic impact on heart rate of infants in the study groups was observed in the result of Holter monitoring, but the absence of changes of sympathetic effect in general. It was reflected by the increase of the value of vagosympathetic index (LF/HF), similarly to this disease suggesting low evidence of respiratory sinusal arrhythmia.
Patients in the "superficial" Serratus Anterior Block (SSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone placed between serratus and latissimus dorsi. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting.
PURPOSE:To provide an antimycotic agent containing a specific imidazole derivative or its acid addition salt as active component, having extremely high antimycotic activity, exhibiting remarkable effect against animal-parasitic fungus and having high safety to man and animal. CONSTITUTION:The objective antimycotic agent contains an imidazole derivative of formula (R is 6-9C straight or branched alkyl) or its acid addition salt as an active component. The compound of formula is e.g. 1-[1-(2-n- hexyloxyphenyl)vinyl]-1H-imidazole, etc. The compound of formula can be orally administered as a mixture with chemotherapeutically permissible diluent and carrier and, if necessary, with other excipient for forming a tablet, etc. It is also locally applicable in the form of ointment, etc.
PURPOSE:To make it possible to adjust the ion concn. in a blood prepn. by packing an ion adjusting medium capable of adjusting a specific blood ion concn. into an ion adjusting chamber having an introducing port and a leading- out port. CONSTITUTION:A bottle needle 2 made of a synthetic resin is inserted and connected to the blood transfusion port of a blood bag in which the blood prepn. is preserved. Roll clamps 4a, 4b are opened to successively pass the preserved blood through a connecting tube 3, the ion adjusting chamber 6a and a blood transfusion tube 10 in this order by utilizing the head difference between the blood bag and the ion adjusting device la of the preserved blood prepn. Blood transfusion is executed by pricking an injection needle to a patient, then adjusting the blood flow velocity by the roll clamp 4b. The ion concn. of the potassium ions in the plasma is lowered by passing the blood prepn. before connection to the blood bag at the time of using, for example, the preserved blood prepn. to an immature baby, etc., and, therefore, the safe use of even the blood prepn. of a long preservation period is possible.
PURPOSE: To obtain a cosmetic, containing ingredients comprising a root extract of Scutellaria baicalensis Georg., an extract of Feoniculi Fructus and a placental extract in combination, not only effective in preventing the suntan but also having beautifying and whitening effects such as prevention and recovery of dermal stains and ephelides. CONSTITUTION: This cosmetic contains an extract of a root of Scutellaria baicalensis Georg. (1.5-10wt.%), an extract of Foeniculi Fructus (1-10wt.%) and a placental extract (1-50wt.%) and has both antisuntan and beautifying and whitening effects. The root extract of the Scutellaria baicalensis Georg. has suppressing actions on the formation of peroxylipids together with suppressing actions on tyrosinase activities (suppressing actions on melanogenesis), ultraviolet light absorbing actions, etc. The extract of the Foeniculi Fructus has suppressing actions on the manifestation of mutation induced by ultraviolet rays and the placental extract extracted from the placenta of cattle, a sheep, etc., has removing actions on active oxygen.  Thereby, the cosmetic has the ultraviolet light absorbing actions, suppressing actions on tyrosinase (suppressing actions on the production of melanin pigments) and the formation of the peroxylipids and further actions as a bioantimutagen.